Intellia draws $75 million from OrbiMed secured debt facility of up to $400 million

Intellia Therapeutics (Nasdaq: NTLA) entered a five-year senior secured credit facility of up to $400 million with OrbiMed and drew $75 million at its September 4 closing, according to its Form 8-K filed that day. Most of the headline amount is not available immediately: further draws depend on milestones, and $100 million is uncommitted.

The financing gives Intellia cash as it prepares for potential U.S. approval and a commercial launch of lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema. Lonvo-z remains investigational. Intellia says the facility also supports development of nexiguran ziclumeran, or nex-z, in ATTR and its early pipeline. The filing identifies working capital needs and general corporate purposes as the uses of proceeds.

Intellia calls the financing non-dilutive in its investor-relations release. It is nevertheless secured debt, with interest, fees and a first-priority security interest in substantially all of the company's assets, including intellectual property. One potential tranche also depends on an equity fundraising target.

The 8-K breaks the facility into five components:

- $75 million drawn on the closing date. - A potential additional $75 million upon FDA approval of the lonvo-z biologics license application before a specified date. - Three potential additional draws of $40 million each upon achieving certain lonvo-z revenue targets before specified dates. - A potential additional $30 million upon achieving an equity fundraising target before a specified date. - An uncommitted incremental facility of up to $100 million, subject to mutual agreement. That amount is not committed capital.

The approval, revenue and fundraising tranches total up to $225 million, the milestone bucket described in the company's release. Their conditions make the timing of lonvo-z approval and subsequent sales relevant to both the development program and access to more financing.

Interest is payable monthly at the greater of 3.00% or one-month SOFR, plus an applicable margin of 6.15%. Then-outstanding principal is due September 4, 2031. The facility also carries customary commitment, administration, undrawn and facility fees, together with a prepayment premium and exit fee.

Until FDA approval of the lonvo-z BLA, Intellia must maintain at least $50 million of liquidity in controlled accounts. That covenant puts a cash requirement alongside the financing's milestone conditions.

The agreement is with OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities V, LP, with the latter serving as administrative agent. Intellia says TD Cowen acted as exclusive financial adviser and Goodwin Procter LLP served as legal adviser.

The next points to watch are the lonvo-z BLA timetable, satisfaction of the additional draw conditions and compliance with the liquidity covenant. Intellia says it will file the full credit agreement with its Form 10-Q for the quarter ending September 30, 2026; that exhibit should provide the detailed terms behind the milestones and fees summarized in the 8-K.